Ultragenyx Pharmaceutical vs TG Therapeutics
Ultragenyx Pharmaceutical and TG Therapeutics are similar in size: $673m and $616m of revenue in their latest fiscal years. TG Therapeutics grew faster (87.3% against 20.2%). TG Therapeutics kept more of each dollar of sales as profit: a net margin of 72.6% against -85.4%.
| Latest fiscal year | Ultragenyx PharmaceuticalRARE, 2025 | TG TherapeuticsTGTX, 2025 |
|---|---|---|
| Revenue | $673m | $616m |
| Revenue growth | 20.2% | 87.3% |
| Net income | −$575m | $447m |
| Operating margin | -79.5% | 20.0% |
| Net margin | -85.4% | 72.6% |
| Return on equity | — | 102.8% |
| Free cash flow | −$472m | −$25.0m |
| Cash | $421m | $79.1m |
| Total debt | $0 | $246m |
| Debt to equity | — | 37.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $91.2m |
| Employees | 1,371 | 399 |
| Market value | $1.65bn | $9.32bn |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 0 buys, 28 sales | 0 buys, 2 sales |